Immatics (IMTX) Cash from Investing Activities (2019 - 2025)
Immatics (IMTX) reported Cash from Investing Activities of -$33.7 million for Q4 2025, up 33.55% on a YoY basis from -$25.2 million in Q4 2024, and down 123.48% sequentially from $143.4 million in Q3 2025.
Immatics (IMTX) Cash from Investing Activities (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Cash from Investing Activities data on file, last reported at -$33.7 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 33.55% year-over-year to -$33.7 million; the trailing twelve-month figure through Dec 2025 stood at $231.7 million (up 240.78% YoY), and the FY2025 full-year result was $231.4 million, up 240.28% from the prior year.
- Cash from Investing Activities retreated to -$33.7 million in Q4 2025, from $143.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $143.4 million in Q3 2025 to a low of -$262.7 million in Q1 2024.
- A 5-year average of -$8.7 million and a median of -$3.0 million in 2023 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 510.15% in 2024, while the deepest fall reached 6481.11% in 2024.
- Tracing IMTX's Cash from Investing Activities over 5 years: stood at -$2.1 million in 2021, then sank by 4300.84% to -$92.0 million in 2022, then jumped by 169.84% to $64.3 million in 2023, then sank by 178.82% to -$50.7 million in 2024, then jumped by 33.55% to -$33.7 million in 2025.
- Business Quant data shows IMTX's Cash from Investing Activities at -$33.7 million in Q4 2025, $143.4 million in Q3 2025, and $72.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Immatics | 1.12 Bn | 578.05 Mn | - | -33.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -33.66 Mn |
| Dec 31, 2025 | -33.66 Mn |
| Sep 30, 2025 | 143.39 Mn |
| Sep 30, 2025 | 143.39 Mn |
| Jun 30, 2025 | 72.73 Mn |
| Jun 30, 2025 | 72.73 Mn |
| Mar 31, 2025 | 49.24 Mn |
| Mar 31, 2025 | 49.24 Mn |
| Dec 31, 2024 | -50.66 Mn |
| Dec 31, 2024 | -50.66 Mn |
| Sep 30, 2024 | 73.59 Mn |
| Sep 30, 2024 | 73.59 Mn |
| Jun 30, 2024 | 75.19 Mn |
| Jun 30, 2024 | 75.19 Mn |
| Mar 31, 2024 | -262.70 Mn |
| Mar 31, 2024 | -262.70 Mn |
| Dec 31, 2023 | 64.27 Mn |
| Dec 31, 2023 | 64.27 Mn |
| Sep 30, 2023 | -76.82 Mn |
| Sep 30, 2023 | -76.82 Mn |